Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

Published:2017-12-04 Issue:2 Volume:93 Page:213-221
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Altman Jessica K.¹^ORCID,Foran James M.²,Pratz Keith W.³^ORCID,Trone Denise⁴,Cortes Jorge E.⁵,Tallman Martin S.⁶

Affiliation:

1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University; Chicago Illinois

2. Division of Hematology and Medical Oncology; Mayo Clinic Florida; Jacksonville Florida

3. Oncology, Johns Hopkins University School of Medicine; Baltimore Maryland

4. Independent consultant; San Diego California

5. Department of Leukemia, Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

6. Leukemia Service, Department of Medicine; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College; New York New York

Funder

Daiichi-Sankyo

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24974/fullpdf

Reference42 articles.

1. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia;Kiyoi;Blood.,1999

2. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials;Kottaridis;Blood.,2001

3. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease;Schnittger;Blood.,2002

4. The impact of FLT3 mutations on the development of acute myeloid leukemias;Testa;Leuk Res Treatment.,2013

5. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis;Thiede;Blood.,2002

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-30

2. Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years;Cancers;2024-08-17

3. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China;Clinical Pharmacology in Drug Development;2024-01-29

4. Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine;Hematology, Transfusion and Cell Therapy;2023-08

5. Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article;Global Medical Genetics;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3